In recent years, advances in drug therapy for head and neck squamous cell carcinoma
(HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as …

Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

Despite the development of standard therapies, including surgery, radiotherapy and
chemotherapy, survival rates for head and neck squamous cell carcinoma (HNSCC) have …

Simple Summary Even with recent advances, there are urgent needs for novel therapies to
improve overall survival and decrease toxicities in the management of head and neck …

Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced
stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti …

Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancers
worldwide. More than half of patients with HNSCC eventually experience disease …

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …

Importance of the field: Head and neck squamous cell carcinoma (HNSCC) is the eighth
leading cause of cancer death worldwide. Despite advances in surgery and chemoradiation …

Despite advances in multimodality therapies for the treatment of squamous cell carcinoma of
the head and neck (SCCHN), survival rates, functional outcomes and toxicities of therapy …

Despite progress in the therapeutic management of patients with squamous cell carcinoma
of the head and neck (SCCHN), the mortality rate of patients presenting with advanced …